NEW YORK – A new CRISPR-based molecular diagnostic for SARS-CoV-2 aims to make COVID-19 screening more equitable and broadly deployed.
As described Thursday in JAMA Network Open, the method — called Cas13-based, rugged, equitable, scalable testing, or CREST — showed high concordance with gold-standard testing.